葉 仲軒

Medicine & Life Sciences

1. Coronary Vessels 100%
2. Hyperlipoproteinemia Type II 94%
3. Percutaneous Coronary Intervention 62%
4. C-Reactive Protein 62%
5. ST Elevation Myocardial Infarction 55%
6. Population 52%
7. Myocardial Infarction 50%
8. Ticagrelor 50%
9. Registries 48%
10. Cohort Studies 43%
11. Coronary Artery Disease 43%
12. Carotid Intima-Media Thickness 42%
13. Calcium 41%
14. Acute Coronary Syndrome 38%
15. Clopidogrel 37%
16. Endothelial Progenitor Cells 37%
17. Mortality 36%
18. Drug-Eluting Stents 35%
19. Vascular Stiffness 35%
20. Coronary Angiography 32%
21. Atherosclerosis 31%
22. Thrombosis 31%
23. oxidized low density lipoprotein 30%
24. Pulmonary Embolism 30%
25. Hypoglycemia 29%
26. Hypertension 28%
27. Blood Vessels 27%
28. Stents 26%
29. Tomography 25%
30. Atherosclerotic Plaques 25%
31. Computed Tomography Angiography 25%
32. Abciximab 24%
33. Serum 24%
34. Angiography 24%
35. Swine 24%
36. Cardiogenic Shock 23%
37. Cardiology 23%
38. Medical Order Entry Systems 22%
39. Left Ventricular Function 22%
40. Heat Stroke 22%
41. Diabetes Mellitus 21%
42. Superior Vena Cava Syndrome 21%
43. N,N-dimethylarginine 21%
44. Takotsubo Cardiomyopathy 20%
45. Survival 20%
46. Inflammation 19%
47. Angioplasty 19%
48. Coronavirus 19%
49. Pregnancy Induced Hypertension 18%
50. Cholesterol 18%